Key Drivers
- Liquidity Buffer
- Margin Pressure
- Cash Burn
AIAI Summary
TWST now looks like a real commercial platform with 13 straight quarters of revenue growth and improving gross margins, but the stock's rich valuation means investors need to see operating leverage and positive cash flow soon—or the ongoing cash burn, debt creep, and uneven demand in NGS could keep the shares under pressure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Buffer
- •Margin Pressure
- •Cash Burn
TWST has solid liquidity and gross margins, but widening losses, negative cash flow, rising debt, and a rich valuation make the stock look expensive relative to current fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Failed rebounds
- •Lower highs/lows
- •Support breakdown
Over the last month, TWST has slipped into a clear downtrend with failed rebounds, lower highs/lows, and a move toward $49-$50 support, while resistance remains $56-$60 and no confirmed reversal is in place.
Sharp drop from $63.20 to $49.17 after repeated rebounds failed
Sentiment & News
Key News Insights:
- •AI demand
- •NGS rebound
- •Product expansion
Twist Bioscience is gaining momentum from AI-driven demand and new collaborations, but near-term losses, softer NGS demand, and ongoing investment keep profitability mixed.
The news is mildly positive for Twist's growth outlook, though margin and earnings execution remain the main near-term risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings